Evidence map›Paper›PMID 24037183›Full record

ArticleCellular & molecular immunology2013

CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells.

Buka Samten

Abstract readComment
In one paragraph

Article in Cellular & molecular immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Single-cell RNA sequencing reveals peripheral blood mononuclear immune cell landscape associated with operational tolerance in a kidney transplant recipient.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023
    Article
  7. Article
  8. Review
  9. Dysregulation of TNature communications · 2021
    Article
  10. Article
  11. Targeted Approaches to T-Cell Lymphoma.Journal of personalized medicine · 2021
    Review
  12. Article
  13. Article
  14. Establishment a CHO Cell Line Expressing Human CD52 Molecule.Reports of biochemistry & molecular biology · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Buka Samten

Funding

Suppression of Allograft Rejection by A Novel Protein ESAT-6R21AI097667 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI SAMTEN, BUKA · 2012 to 2013
$388k
ESAT-6 primes dendritic cells with reduced IL-12 and increased IL-23 productionR21AI099345 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI SAMTEN, BUKA · 2012 to 2013
$388k
NIAID NIH HHS AI097667NIAID NIH HHS AI099345NIAID NIH HHS R21 AI097667NIAID NIH HHS R21 AI099345
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntigens, CDAntigens, NeoplasmCD4-Positive T-LymphocytesDiabetes Mellitus, Type 1FemaleGlycoproteinsHumansLymphocyte ActivationMaleSialic Acid Binding Immunoglobulin-like LectinsAntigens, CDAntigens, NeoplasmGlycoproteinsSialic Acid Binding Immunoglobulin-like Lectins

Identifiers

PMID24037183
PMCPMC4002393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.